SequelSEC

HERON THERAPEUTICS, INC. /DE/ HRTX

Pharmaceutical Preparations · CIK 0000818033 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$151.18M
Fiscal year ended 2026-06-30
Operating income
-$10.86M
Fiscal year ended 2026-06-30
Free cash flow
-$12.14M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$235.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.25Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity16.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue8.0%12th
CapEx / revenue0.2%16th
Operating margin-1.6%79th
SBC / revenue6.7%26th
Net margin-13.0%69th
Current ratio2.48x34th
FCF margin-18.0%61th
Revenue YoY growth7.4%54th
Gross margin73.3%54th

HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $151.18M and net income of -$34.05M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from HERON THERAPEUTICS, INC. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

HERON THERAPEUTICS, INC. /DE/ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$151.18M
Cost of revenue$45.24M
Gross profit$105.94M
Operating income-$10.86M
Net income-$34.05M
Research & development$12.30M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$104.50M
General & administrative$50.85M
Selling & marketing$53.64M

Balance

HERON THERAPEUTICS, INC. /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$20.72M
Total assets$252.26M
Current assets$229.84M
Total liabilities$245.35M
Current liabilities$92.14M
Total equity incl. NCI$6.91M
Temporary (mezzanine) equityUnavailable
Inventory$90.58M
Accounts receivable$89.57M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$11.64M

Cash flow

HERON THERAPEUTICS, INC. /DE/ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.61M
Capital expenditures$529.00K
Investing cash flow$2.20M
Financing cash flow$13.61M
Net change in cash$4.20M
Stock-based compensation$11.18M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.13M

Derived

HERON THERAPEUTICS, INC. /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$12.14M
Gross margin70.1%
Operating margin-7.2%
FCF margin-8.0%
SBC / revenue7.4%
Current ratio2.49x
Revenue YoY growth1.0%
Net margin-22.5%
R&D / revenue8.1%
CapEx / revenue0.3%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HRTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.